1-<2-<<4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl>methoxy>ethyl>-3-<(ethoxycarbonyl)methyl>urea | 97290-23-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-<2-<<4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl>methoxy>ethyl>-3-<(ethoxycarbonyl)methyl>urea
• 英文别名: 1-<2-{[4-(2-chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy}ethyl>-3-(ethoxycarbonylmethyl)urea；3-O-ethyl 5-O-methyl 4-(2-chlorophenyl)-2-[2-[(2-ethoxy-2-oxoethyl)carbamoylamino]ethoxymethyl]-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 97290-23-8
• 化学式: C₂₅H₃₂ClN₃O₈
• 分子量: 537.997
• InChiKey: KOXIZIAELLUGPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  37
• 可旋转键数：
  15
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  141
• 氢给体数：
  3
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  1-<2-<<4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl>methoxy>ethyl>-3-<(ethoxycarbonyl)methyl>urea 在 ammonium hydroxide 作用下， 以 甲醇 为溶剂， 反应 16.0h， 以21%的产率得到1-<2-{[4-(2-Chlorophenyl)-3-ethoxycarbonyl-5-methoxycarbonyl-6-methyl-1,4-dihydropyridin-2-yl]methoxy}ethyl>imidazolidine-2,5-dione
  参考文献：
  名称：

  长效二氢吡啶类钙拮抗剂。5.一系列2-[[[（N-取代-杂环基）乙氧基]甲基] -1,4-二氢吡啶钙拮抗剂的合成与构效关系。

  摘要：

  描述了一系列在1位乙氧基甲基链的末端具有N-连接的杂环的1，4-二氢吡啶的合成。通过使用Langendorff灌注的豚鼠心脏模型确定，将这类DHP对大鼠主动脉的钙拮抗剂活性与其负性肌力活性进行比较。所检查的化合物对心脏组织的血管显示出广泛的选择性，在2-取代基末端具有酰胺基的那些类似物被证明具有最高的选择性。根据一系列1,2,3-三唑的体外数据，可以得出结论，与血管和心脏组织中钙通道结合的SAR不同。化合物之一是2-氨基-1- [2-[[4-（2,3-二氯苯基）-3-（乙氧羰基）-5-（甲氧羰基）-6-甲基-1

  DOI：

  10.1021/jm00168a041
• 作为产物：
  描述：

  氨氯地平 、 异氰酰乙酸乙酯 以 乙腈 为溶剂， 反应 2.5h， 以86%的产率得到1-<2-<<4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6-methyl-1,4-dihydropyrid-2-yl>methoxy>ethyl>-3-<(ethoxycarbonyl)methyl>urea
  参考文献：
  名称：

  Long-acting dihydropyridine calcium antagonists. 4. Synthesis and structure-activity relationships for a series of basic and nonbasic derivatives of 2[(2-aminoethoxy)methyl]-1,4-dihydropyridine calcium antagonists

  摘要：

  The preparation of a series of 1,4-dihydropyridines (DHPs) which have polar, acyclic, nonbasic substituents on an ethoxymethyl chain at the 2-position is described. In addition, in order to assess the effects of incorporating a basic center into DHPs of this type, a series of glycinamides were also prepared. The calcium antagonist activity on rat aorta of both these classes of DHP is compared with their negative inotropic activity as determined by using a Langendorff perfused guinea pig heart model. A number of the compounds evaluated have activity of the same order as nifedipine although those with more extended substituents have lower potency, particularly when a basic substituent is present. The compounds examined displayed a wide variation in selectivity for vascular over cardiac tissue. A number of structure-activity relationship trends were identified and possible explanations to account for the differences in selectivity observed are advanced. One of the compounds, 2-[[2-[[4-(2-chlorophenyl)-3-(ethoxycarbonyl)-5-(methoxycarbonyl)-6- methyl-1,4-dihydropyrid-2-yl]methoxy]ethyl]amino]acetamide (26, UK-51,656), was identified as a potent (IC50 = 4 x 10(-9) M) calcium antagonist which is 20-fold selective for vascular over cardiac tissue and which has a markedly longer duration of action (greater than 5 h) than nifedipine in the anesthetized dog on intravenous administration. The pharmacokinetic half-life of 26 was established as 4.7 h and possible explanations are advanced to account for 26 having a shorter plasma half-life than amlodipine and a longer plasma half-life than felodipine.

  DOI：

  10.1021/jm00164a019

文献信息

• 2-(4-Pyrimidone alkoxyalkyl) dihydropyridine anti-ischaemic and
  申请人：Pfizer Inc.

  公开号：US04568677A1

  公开（公告）日：1986-02-04

  1,4-Dihydropyridine derivatives of the formula: ##STR1## wherein R is aryl or heteroaryl; R.sup.1 and R.sup.2 are each independently C.sub.1 -C.sub.4 alkyl or 2-methoxyethyl; X is a 5 or 6 membered nitrogen-containing heterocyclic ring which is substituted with one or more hydroxyl or oxo groups and which may optionally be fused to a further 5 or 6 membered nitrogen-containing heterocyclic ring, and which may optionally be further substituted in the heterocyclic ring or further fused heterocyclic ring; Y is --(CH.sub.2).sub.n --, --CH.sub.2 CH(CH.sub.3)-- or --CH.sub.2 C(CH.sub.3).sub.2 --; and n is 1 to 3 when X is linked to Y by a ring carbon atom, or 2 or 3 when X is linked to Y by a ring nitrogen atom; and their pharmaceutically acceptable salts, and pharmacuetical preparation containing such compounds, have utility as anti-ischaemic and antihypertensive agents.

  1,4-二氢吡啶衍生物的化学式为：##STR1## 其中R为芳基或杂环芳基；R.sup.1和R.sup.2分别独立为C.sub.1 -C.sub.4烷基或2-甲氧基乙基；X为含氮的5或6成员杂环环，其上取代有一个或多个羟基或氧代基，且可能选择性地与另一个含氮的5或6成员杂环环融合，在杂环环中或进一步融合的杂环环中可能进一步取代；Y为--(CH.sub.2).sub.n --，--CH.sub.2 CH(CH.sub.3)--或--CH.sub.2 C(CH.sub.3).sub.2 --；当X由环碳原子与Y连接时，n为1至3，或当X由环氮原子与Y连接时，n为2或3；它们的药学上可接受的盐，以及含有这些化合物的药物制剂，具有作为抗缺血和降压药物的用途。
• Dihydropyridine anti-ischaemic and antihypertensive agents
  申请人：Pfizer Limited

  公开号：EP0132375A2

  公开（公告）日：1985-01-30

  1,4-Dihydropyridine derivatives of the formula: wherein R is aryl or heteroaryl; R1 and R are each independently C1-C4 alkyl or 2-methoxyethyl; X is a 5 or 6 membered nitrogen-containing heterocyclic ring which is substituted with one or more hydroxyl or oxo groups and which may optionally be fused to a further 5 or 6 membered nitrogen-containing heterocyclic ring, and which may optionally be further substituted in the heterocyclic ring or further fused heterocyclic ring; Y is -(CH2)n-, -CH2CH(CH3)- or-CH2C(CH3)2-; and n is 1 to 3 when X is linked to Y by a ring carbon atom, or 2 or 3 when X is linked to Y by a ring nitrogen atom; and their pharmaceutically acceptable salts, and pharmaceutical preparation containing such compounds, have utility as anti-ischaemic and antihypertensive agents.

  式中的 1,4-二氢吡啶衍生物： 其中 R 是芳基或杂芳基；R1 和 R 各自独立地是 C1-C4 烷基或 2-甲氧基乙基；X 是 5 或 6 位含氮杂环，该杂环被一个或多个羟基或氧代基团取代，并可任选与另一个 5 或 6 位含氮杂环融合，且可任选在杂环或进一步融合的杂环中被进一步取代；Y是-(CH2)n-、- CH(CH3)-或- C( )2-；当X通过环碳原子与Y相连时，n是1至3，当X通过环氮原子与Y相连时，n是2或3；它们的药学上可接受的盐和含有这些化合物的药物制剂可用作抗缺血性和抗高血压药物。
• ALKER, DAVID;CAMPBELL, SIMON F.;CROSS, PETER E.;BURGES, ROGER A.;CARTER, +, J. MED. CHEM., 33,(1990) N, C. 585-591
  作者：ALKER, DAVID、CAMPBELL, SIMON F.、CROSS, PETER E.、BURGES, ROGER A.、CARTER, +

  DOI：——

  日期：——
• ALKER, DAVID;CAMPBELL, SIMON F.;CROSS, PETER E.;BURGES, ROGER A.;CARTER, +, J. MED. CHEM., 33,(1990) N, C. 1805-1811
  作者：ALKER, DAVID、CAMPBELL, SIMON F.、CROSS, PETER E.、BURGES, ROGER A.、CARTER, +

  DOI：——

  日期：——